Related references
Note: Only part of the references are listed.Drosophila Cancer Models Identify Functional Differences between Ret Fusions
Sarah Levinson et al.
CELL REPORTS (2016)
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
Elisa Caiola et al.
ONCOTARGET (2015)
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
Mirko Marabese et al.
ONCOTARGET (2015)
Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response
Elda Grabocka et al.
CLINICAL CANCER RESEARCH (2015)
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
Saveri Bhattacharya et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2015)
Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
Sheila Piva et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer with a KRAS Mutation
Anne-Marie C. Dingemans et al.
CLINICAL CANCER RESEARCH (2013)
Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations
Xiang-Hua Zhang et al.
CANCER LETTERS (2012)
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients Eastern Cooperative Oncology Group Study E2501
Heather A. Wakelee et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
M. C. Garassino et al.
ANNALS OF ONCOLOGY (2011)
Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib
Ronan J. Kelly et al.
CLINICAL CANCER RESEARCH (2011)
WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
Philip C. De Witt Hamer et al.
CLINICAL CANCER RESEARCH (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
Pathological roles of MAPK signaling pathways in human diseases
Eun Kyung Kim et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2010)
In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma
Shahryar E. Mir et al.
CANCER CELL (2010)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets
Elizabeth Iorns et al.
PLOS ONE (2009)
Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis
Steffen Blenk et al.
BMC CANCER (2008)
SnapShot: Ras signaling
Megan Cully et al.
CELL (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement
Taija M. Kiviharju-af Hallstrom et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Hyperactive Ras in developmental disorders and cancer
Suzanne Schubbert et al.
NATURE REVIEWS CANCER (2007)
The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer
T Yoshida et al.
ANNALS OF ONCOLOGY (2004)
Cyclins and cyclin-dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis
T Masaki et al.
HEPATOLOGY (2003)